Endocrine therapies targeting the proliferative effect of 17b-estradiol through estrogen receptor a (ERa) are the most effective systemic treatment of ERa-positive breast cancer. However, most breast tumors initially responsive to these therapies develop resistance through molecular mechanisms that are not yet fully understood. The longterm estrogen-deprived (LTED) MCF7 cell model has been proposed to recapitulate acquired resistance to aromatase inhibitors in postmenopausal women. To elucidate this resistance, genomic, transcriptomic and molecular data were integrated into the time course of MCF7-LTED adaptation. Dynamic and widespread genomic changes were observed, including amplification of the ESR1 locus consequently linked to an increase in ERa. Dynamic transcriptomic profiles were also observed that correlated significantly with genomic changes and were predicted to be influenced by transcription factors known to be involved in acquired resistance or cell proliferation (for example, interferon regulatory transcription factor 1 and E2F1, respectively) but, notably, not by canonical ERa transcriptional function. Consistently, at the molecular level, activation of growth factor signaling pathways by EGFR/ERBB/AKT and a switch from phospho-Ser118 (pS118)-to pS167-ERa were observed during MCF7-LTED adaptation. Evaluation of relevant clinical settings identified significant associations between MCF7-LTED and breast tumor transcriptome profiles that characterize ERa-negative status, early response to letrozole and tamoxifen, and recurrence after tamoxifen treatment. In accordance with these profiles, MCF7-LTED cells showed increased sensitivity to inhibition of FGFR-mediated signaling with PD173074. This study provides mechanistic insight into acquired resistance to endocrine therapies of breast cancer and highlights a potential therapeutic strategy.
Endocrine therapies targeting the proliferative effect of 17b-estradiol through estrogen receptor a (ERa) are the most effective systemic treatment of ERa-positive breast cancer. However, most breast tumors initially responsive to these therapies develop resistance through molecular mechanisms that are not yet fully understood. The longterm estrogen-deprived (LTED) MCF7 cell model has been proposed to recapitulate acquired resistance to aromatase inhibitors in postmenopausal women. To elucidate this resistance, genomic, transcriptomic and molecular data were integrated into the time course of MCF7-LTED adaptation. Dynamic and widespread genomic changes were observed, including amplification of the ESR1 locus consequently linked to an increase in ERa. Dynamic transcriptomic profiles were also observed that correlated significantly with genomic changes and were predicted to be influenced by transcription factors known to be involved in acquired resistance or cell proliferation (for example, interferon regulatory transcription factor 1 and E2F1, respectively) but, notably, not by canonical ERa transcriptional function. Consistently, at the molecular level, activation of growth factor signaling pathways by EGFR/ERBB/AKT and a switch from phospho-Ser118 (pS118)-to pS167-ERa were observed during MCF7-LTED adaptation. Evaluation of relevant clinical settings identified significant associations between MCF7-LTED and breast tumor transcriptome profiles that characterize ERa-negative status, early response to letrozole and tamoxifen, and recurrence after tamoxifen treatment. In accordance with these profiles, MCF7-LTED cells showed increased sensitivity to inhibition of FGFR-mediated signaling with PD173074. This study provides mechanistic insight into acquired resistance to endocrine therapies of breast cancer and highlights a potential therapeutic strategy.
Introduction
Endocrine therapies are the most effective systemic treatment of estrogen receptor a (ERa)-positive breast cancer, and over two-thirds of patients are considered to present with this kind of disease (EBCTCG, 1998; Chlebowski et al., 2002; Winer et al., 2002) . Two major strategies mediate the efficacy of these therapies. Drugs directed at ERa, mainly tamoxifen and fulvestrant, impede its binding to 17b-estradiol (17bE2) and, as a result, canonical ERa-dependent transcriptional regulation (Dowsett et al., 2005b) . In contrast, the activity of aromatase inhibitor (AIs), which are the most effective treatment of breast cancer in postmenopausal women (the largest group of patients), is based on almost complete deprivation of estrogen production (Geisler et al., 2002) . However, although endocrine therapies are initially effective, resistance occurs both in the form of tumor relapse after excision during adjuvant treatment and as a near-universal event when tumors cannot be excised. Importantly, acquired resistance is not commonly associated with the conversion to ERa-negative of previous ERa-positive breast tumors. Nevertheless, changes in ERa expression have been found in some series (Johnston et al., 1995) .
Current literature supports the hypothesis that acquired resistance is mainly mediated by molecular events that-particularly in the case of resistance to AIs-lead to constitutive activation of ERa and growth factor signaling pathway cross-talk (Clarke et al., 2003; Martin et al., 2003; Yue et al., 2003; Jelovac et al., 2005; Normanno et al., 2005; Sabnis et al., 2005; Santen et al., 2005; Masri et al., 2008) . On the basis of these studies, several clinical trials have attempted to overcome resistance through combination with growth factor signaling inhibitors Massarweh and Schiff, 2006) . However, results of these trials are relatively insufficient and, therefore, deeper knowledge of the mechanism of acquired resistance is needed. In this study, we use a well-known model of acquired resistance to AIs (that is, MCF7-LTED) to comprehensively analyze the mechanism underpinning adaptation to estrogen deprivation in ERa-positive breast cancer. The novelty of our approach derives from two key characteristics: the description of dynamic genomic, transcriptomic and molecular changes; and the integrative analysis of these biological data levels to delineate the adaptive phenomena. Together, our data suggest a mechanism for acquired resistance that is mostly independent of canonical ERa transcriptional function and coordinated across biological levels.
Results
Molecular changes during MCF7-LTED adaptation are consistent with growth signaling pathway cross-talk To generate a breast cancer cell model of acquired resistance to AIs, MCF7 cells were cultured in a medium depleted of 17bE2, as described previously (Katzenellenbogen et al., 1987; Welshons and Jordan, 1987; Masamura et al., 1995; Jeng et al., 1998; Stephen et al., 2001; Chan et al., 2002) . After initial quiescence for approximately 60 days, cell cultures adapted at 90 days, defined by a diminished proliferation-dependent response from 17bE2 ( Figure 1a ). The proliferation profile and time lapse for resistance are in agreement with previous studies (Yue et al., 2003; Martin et al., 2005; Shaw et al., 2006; Sadler et al., 2009) . At the latter time point evaluated in this study, MCF7-LTED cells are thought to be in 17bE2-hypersensitive status, which should be acquired at between 3-6 months in 17bE2-deprived culture and precedes acquisition of full 17bE2 independence (Masamura et al., 1995; Santen et al., 2001; Chan et al., 2002; Martin et al., 2003) .
Molecular characterization of the MCF7-LTED model showed activation of AKT in the form of phospho-Serine473 (pS473) and overexpression of total epidermal growth factor receptor, ERBB2 and ERBB4 but not ERBB3 (Figure 1b) . Activation of AKT and overexpression of EGF and ERBB receptors are consistent with previous observations in MCF7-LTED cells and related breast cancer conditions (Masamura et al., 1995; Jeng et al., 1998; Shim et al., 2000; McClelland et al., 2001; Knowlden et al., 2003; Osborne et al., 2005; Yue et al., 2005; Song et al., 2006; Beeram et al., 2007; LewisWambi et al., 2008; Santen et al., 2008; Ghayad et al., 2009) . Notably, ERBB2 amplification was associated with resistance to endocrine therapies (Ellis et al., 2006) , and treatment with the mTOR inhibitor RAD001 increased letrozole efficacy in a neoadjuvant setting of ERa-positive breast cancer (Baselga et al., 2009) .
Despite the observed increase in growth factor receptor levels, the largest molecular differences relative to the parental MCF7 cells were in progesterone receptor and ERa expressions. Consistent with previous studies (Jeng et al., 1998; Shim et al., 2000; Stephen and Darbre, 2000; Martin et al., 2003; Shaw et al., 2006; Santen et al., 2008; Sadler et al., 2009) , progesterone receptor was found to be strongly underexpressed, whereas ERa was strongly overexpressed in MCF7-LTED extracts ( Figure 1c) . Next, evaluation of activated forms of ERa revealed increased pS167 and pS305 but not pS118 (Figure 1c) . Importantly, the major phosphorylation site in response to 17bE2 was previously demonstrated to be S118, whereas S167 is only modified in response to MAPK/AKT pathway signaling (Lannigan, 2003) . In addition, pS305 was associated with resistance to tamoxifen treatment (Michalides et al., 2004) . According to these observations, subcellular fractionation assays showed relatively higher levels of ERa in the cytoplasm of MCF7-LTED cells (Figure 1d ). Higher levels of pS305 were also observed in the nuclear fraction of MCF7-LTED cells, whereas the level of pS118 was higher in the cytoplasm of the parental MCF7 cells (Figure 1d ). Collectively, these data support the relevance of ERa and growth factor signaling pathway cross-talk in acquired resistance (Dowsett et al., 2005a; Massarweh and Schiff, 2007) and, accordingly, the validity of the MCF7-LTED model for delineating the underlying mechanism.
Dynamic and extensive genomic changes, including ESR1, during adaptation to 17bE2 deprivation Although molecular alterations are seen to occur during the establishment of the MCF7-LTED model, the extent, time course and biological impact of genomic changes contributing to adaptation are unknown. To evaluate these changes, DNA samples from MCF7 cultures were taken at five time points between 0-150 days after 17bE2 deprivation and subsequently hybridized against a high-density single nucleotide polymorphism platform (see Materials and methods). Copy number alterations were defined with the Bayesian approach in the Genome Alteration Detection Analysis algorithm (Pique-Regi et al., 2008) and change trends computed using the Goodman-Kruskal gamma (G) coefficient. With |G| ¼ 1 (Po0.001), a dynamic shift through adaptation to 17bE2 deprivation was observed at many loci (Figure 2a) . A marked transition was observed at the 90-day time point, akin with the resistance phenotype defined above. Notably, between days 0 and 150, a total of B360 and B550 Mega bases (Mb) were lost and gained, respectively. Changes involved most chromosomes, except 9, 10, 16, 17 and 19 (data not shown).
Although a large proportion of these genomic changes might be randomly selected (that is, passenger) relative to adaptation to 17bE2 deprivation-due to inherent genomic instability and clonal selection-the transcriptomic and biological annotation data analyses Effect of 17bE2 through ERa H Aguilar et al presented below point to causally implicated changes (that is, drivers). Of the putative driver loci, the region containing ESR1 showed a significant gain at the days 120-150 time point relative to 0-90 ( Figure 2b , left panel). Thus, the maximum gain in chromosome 6q was detected at rs6939257 (log R ratio ¼ 0.38, corresponding to a 2.4-fold gain at 150 days), which is located B40 kb proximal to the 5 0 -exon of ESR1. Importantly, consistent results were observed across time points and concurrently highlighted by allelic imbalances at the same region ( Figure 2b , right panel). Intriguingly, ESR1 locus gain appeared to be accompanied by accentuated losses of distal parts of the same chromosome arm (Figure 2b ). The relatively late time points at which this gain was manifested relative to ESR1 overexpression ( Figure 2c ) suggest that transcriptional regulation has a major role at the transition, whereas genomic gain might participate in the settlement of resistance. Notably, all ESR1 probes in the microarray platform showed a trend for overexpression but none passed significance correction using the false discovery rate approach (nominal P-values o0.05 for seven out of nine probes); however, quantitative analysis revealed significant overexpression (subsequent sections). Together, these observations suggest that dynamic genomic and transcriptional changes has an important role in acquired resistance.
Correlation between genomic and transcriptomic changes, and the link to non-genomic function of ERa To corroborate genomic changes and assess their consequences at the transcriptomic level, we examined genome-wide expression profiles at similar time points to those indicated above. Differential expression was defined using linear regression modeling with estimates of significance corrected by the false discovery rate approach (Benjamini and Hochberg, 1995) . Consistent with the changes described above, a marked transition Table 1) .
As supported by the molecular data presented above, acquired resistance may be mediated by constitutive activation of ERa and growth factor signaling pathway cross-talk (Martin et al., 2003; Jelovac et al., 2005; Sabnis et al., 2005; Santen et al., 2005; Masri et al., 2008) . Thus, the identities of genes differentially expressed during MCF7-LTED adaptation may support the important role of the non-genomic function of ERa. GATA3, which encodes for a key transcription factor for luminal differentiation tightly coregulated with and by ERa in breast cancer cells (Eeckhoute et al., 2007; Kouros-Mehr et al., 2008) , showed significant underexpression during MCF7-LTED adaptation (Figure 3b ). In contrast, RAF1, which encodes for a key factor in mitogen-activated protein kinase signaling and the associated resistance to tamoxifen treatment (Iorns et al., 2008) , showed significant overexpression ( Figure 3b ). Evaluation of these observations-and of ESR1-by quantitative reverse transcription polymerase chain reaction (quantitative reverse transcriptase (qRT)-PCR) and/or by western blotting assays corroborated the overexpression of ESR1 and RAF1 in MCF7-LTED cells (Figure 3d , left panel, and e, and Supplementary Table 2 ). Although a trend was observed, GATA3 expression change was not confirmed by qRT-PCR assays (Figure 3d , left panel), which might be because of alternative splicing patterns for this gene (Stamm et al., 2006) detected in MCF7 cells (Hoch et al., 1999) . Finally, in accordance with the molecular characterization above (Figure 1b) , EGFR also showed significant overexpression in the microarray dataset (Figure 3b ). Taken together, these data further support pathway cross-talk, whereas suggest a transition toward a transcriptomic program independent of canonical ERa transcriptional function.
Transcriptional reprogramming independent of canonical ERa function linked to breast cancer prognostic and predictive signatures To delineate the regulation of transcriptomic changes during MCF7-LTED adaptation, the representation of predicted transcription factor binding sites (TFBSs) at promoters was evaluated using predictions from the STORM algorithm (Schones et al., 2007) and position 
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H Aguilar et al frequency matrices from TRANSFAC (Matys et al., 2006) and JASPAR (Bryne et al., 2008) . Thus, both under-and overexpressed gene sets during adaptation were found to be enriched in a TFBS of ZFX ( Figure 4a , bottom panels), a transcription factor involved in stem cell self-renewal (Galan-Caridad et al., 2007) . The underexpressed set was found to be enriched in TFBSs principally of the interferon regulatory transcription factor (IRF) family (Figure 4a ). Notably, IRF1 activity was previously demonstrated to be critical in response to endocrine therapies through promoting apoptosis (Gu et al., 2002; Bouker et al., 2004; Bowie et al., 2004) . In contrast, the overexpressed set principally showed enrichment in E2Fs and SP1 TFBSs (Figure 4a ). IRF1 probes in the microarray dataset indicated underexpression but none reached statistical significance: however, qRT-PCR and/or western assays confirmed the predicted expression changes for IRF1 as well as for E2F1/ E2F1 and MYC (Figure 4b ). According to these observations, the overexpressed set showed enrichment in the Gene Ontology biological process 'DNA metabolic process' (false discovery rate-adjusted P ¼ 0.01) and its corresponding parent terms (data not shown). Moreover, gene markers of cell cycle or proliferation were found in this set: for example, CCNA1, PCNT, POLD1 and TERF1 (Figure 3d ), three of which were corroborated by qRT-PCR assays (Figure 3d, right  panel) . Together, these data suggest a link with a cell 'proliferation-on' transcriptional program with inhibition of apoptosis, as commonly observed in poor prognosis and non-response treatment expression profiles in breast cancer (Sole´et al., 2009) . To further evaluate the depicted transcriptional program, we examined expression correlations between gene sets and the corresponding TF genes across a large series of breast tumors (van de Vijver et al., 2002) . Significant correlations between the expression profiles of under-and/or overexpressed sets and E2F1, IRF1, IRF7 and SP1 were identified relative to randomly selected equivalent gene sets (Po10 À3 ) (Figure 4c , top left panels show results for E2F1). In addition, the overexpressed set showed coexpression with MYC (Figure 4c , top right panels), which is consistent with TFBSs predictions (Figure 4a ) and the role of MYC regulation of poor outcome signatures (Adler et al., 2006; Wolfer et al., 2010) . Significant coexpression was also observed for ZFX (Figure 4c , bottom left panels), although with an opposite pattern that suggests a differential effect on transcriptional regulation during acquired resistance. A similar relationship was observed for coexpression with ESR1 (Figure 4c , right bottom panels), in agreement with the acquisition of a transcriptional program that may be mostly independent of canonical ERa transcriptional function, which therefore resembles ERa negativity (subsequent sections). 
Transcriptional reprogramming was further evaluated using data on chromatin immunoprecipitation assays (that is, genomic response elements) and expression profiles linked to cell proliferation and canonical ERa transcriptional function (Balciunaite et al., 2005; Carroll et al., 2006; Xu et al., 2007) . In agreement with TFBSs predictions and breast cancer profiles, the underexpressed set showed infra-representation of E2F1-AP2 
H Aguilar et al response elements (P ¼ 0.041), whereas the overexpressed set showed enrichment of the same elements (P ¼ 0.022). Analysis of an independent dataset (Balciunaite et al., 2005) showed similar results for E2F4 response elements (underexpressed set, infra-representation P ¼ 0.072; overexpressed set, supra-representation P ¼ 0.003). However, neither under-nor overexpressed sets showed variation relative to random in the content of transcripts regulated through 17bE2 (PX0.30). Moreover, both sets showed infra-representation of ERa response elements detected in MCF7 cells (Po0.010). Collectively, these observations further support the acquisition of a cell proliferation-on transcriptional program that is mostly independent of canonical ERa transcriptional function.
Mechanistic insight into response to endocrine therapies
The genomic, transcriptomic and molecular changes observed during MCF7-LTED adaptation are compatible with common features of breast cancer prognostic and predictive signatures (Sole´et al., 2009). Further insight into breast cancer biology and treatment was obtained through the examination of expression profiles that characterize ERa tumor status and letrozole and tamoxifen responses (van de Vijver et al., 2002; Ma et al., 2004; Miller et al., 2007) . This analysis was performed using the non-parametric algorithm in the gene set enrichment analysis tool (Subramanian et al., 2005) . When comparing ERa-positive and -negative tumors, significant asymmetrical distributions of expression values were detected: genes overexpressed during MCF7-LTED adaptation had higher expression values in ERa-negative tumors (P ¼ 0.024), whereas underexpressed genes had higher expression values in ERapositive tumors (P ¼ 0.023) (Figure 5a ). These results support the data obtained from the transition of ERapositive MCF7 to MCF7-LTED cells which, although maintaining ERa positivity, as commonly occurs in the clinical setting, suggests a different role of ERa. In further support of this transition and its potential clinical impact, significant overexpression of key genes recently described in triple-negative breast tumors was also detected, including the therapeutic target fibroblast growth factor receptor 2 (FGFR2) (Figure 5b ) (Turner et al., 2010a) . In this set, the expression changes of CSNK1D and FGFR2 were assessed and subsequently corroborated by qRT-PCR and western blot assays (Figure 5c ). Examination of tamoxifen treatment response (Ma et al., 2004) revealed association of overexpressed genes with recurrence (P ¼ 0.008; underexpressed genes showed a trend with non-recurrence, P ¼ 0.13): specifically, overexpressed genes during MCF7-LTED adaptation had higher expression levels in tumors that were recurrent (Figure 5d ), in accordance with their link to cell proliferation and ERa-negative tumor status. In addition, endorsing the importance of long-term transcriptional reprogramming in the clinical scenario, genes overexpressed early and strongly with tamoxifen treatment in normal mammary epithelial cells (Schild-Hay Examination of early transcriptional response to letrozole treatment (before and after 14 days of treatment (Miller et al., 2007) ) revealed significant differences in the expression of the overexpressed set between pre-and post-treatment samples (P ¼ 0.022) (Figure 5f ). Conversely to the immune response set above, genes downregulated immediately after letrozole treatment exhibited overexpression in MCF7-LTED adaptation, again akin to the role of this set in cell proliferation and consistent with the profiles at early MCF7-LTED time points (Figure 3) . Although underexpressed genes during MCF7-LTED adaptation did not show association with letrozole treatment (P ¼ 0.30; Figure 5f ), expression data for wider time points after treatment will be necessary to comprehensively evaluate this subject, as this study shows dynamic profiles in acquired resistance. Therefore, although endocrine therapies may temporarily reduce tumor growth or size, this study proposes that the expression of key gene sets will be recovered and eventually increase-or, conversely, be reduced for the immune response set-to produce resistant tumors.
Potential second-line therapeutic strategies Previous MCF7-LTED models have shown sensitivity to further antiestrogenic treatment with fulvestrant (ICI 182 780), which acts as a pure antagonist leading to ERa degradation (Santen et al., 2001; Chan et al., 2002; Martin et al., 2003; Dowsett et al., 2005b) . Following these observations, and as a potential second-line therapeutic strategy, we assessed the effect of ICI 182 780 using late-stage (that is, 18 months) MCF7-LTED cells and their parental MCF7 cells. Notably, MCF7-LTED cells were relatively less sensitive to ICI 182 780 (Figure 6a , including controls of ERa and CDK4 levels, right panels), which further supports the hypothesis of full 17bE2 independence at a late time point, but it is in apparent contradiction with previous evidence (Santen et al., 2001; Chan et al., 2002; Martin et al., 2003) . An explanation for this discrepancy may be found in the examination of different time points, as there are possibly dynamic profiles after six months in 17bE2-deprived culture. Next, having identified the Effect of 17bE2 through ERa H Aguilar et al activation of growth factor signaling pathways and, in particular, of FGFR2/FGFR2 overexpression (Figure 5c ), we sought to evaluate the effects of targeting FGFRmediated signaling using the inhibitor PD173074 (Korc and Friesel, 2009) . In this study, MCF7-LTED cells showed increased sensitivity to PD173074 relative to parental cells in a dose-response manner (Figure 6b) . Importantly, similar effects have recently been described in models of triple-negative and endocrine-resistant (to tamoxifen) breast cancer (Turner et al., 2010a, b) , which further endorses the existence of reprogramming across different biological levels but partially independent of canonical ERa transcriptional function.
Discussion
When not fully excised, almost all breast tumors showing ERa positivity develop resistance to endocrine therapies. Metastatic breast cancer, in which the spread of cancer cells impedes surgical removal, is the paradigmatic clinical scenario that recapitulates this fact. In the majority of these cases, most effective first-line therapies achieve patient response rates no higher than 50% (Jonat et al., 1995) . Even after a period of disease control, resistance appears in those cases previously considered sensitive, and second-line therapies achieve disease control rates of little higher than 20% for shorter Figure 5 Association with breast cancer pathological and clinical features. (a) In GSEA, the results of the statistical analysis of gene expression data are rank-ordered from the largest positive change to the largest negative change (the red-blue profile at the bottom of each graph). Next, a gene set is mapped to this distribution (black bar code) to assess potential bias using an enrichment score that reflects the degree to which this set is overrepresented at the extremes (top or bottom) of the entire ranked list. Here, GSEA outputs including the enrichment scores and the corresponding P values of the non-parametric analysis are shown. Association with ERa tumor status: left panel, overexpressed genes during MCF7-LTED adaptation had higher expression values in ERa-negative than in ERa-positive tumors; right panel, conversely, underexpressed genes during MCF7-LTED adaptation had higher expression values in ERa-positive than in ERa-negative tumors. (b) Expression profiles during MCF7-LTED adaptation of key genes overexpressed in triple-negative breast tumors (Turner et al., 2010a) . ( 
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H Aguilar et al periods of time (Rose et al., 2003) . At the molecular level, however, ERa usually remains expressed in tumors that were initially sensitive but subsequently develop resistance. Our data are consistent with this observation, providing an explanation based on biological reprogramming independent of canonical ERa transcriptional function. One of the most common hypotheses for the mechanism of resistance to AIs is that, following 17bE2 deprivation, growth factor signaling cross-talk modulates ERa, turning it into a supersensitive receptor able to regulate transcription in the presence of traces of estrogens or even independently of them. This theory implies that, although resistant to estrogen deprivation, these tumors are still dependent on ERa as a major driver of cell biology. The apparent sensitivity of MCF7-LTED cells to further antiestrogenic treatment such as fulvestrant (Santen et al., 2001; Chan et al., 2002; Martin et al., 2003) substantiates this theory, leading to the proposal of clinical trials including these treatments and/or growth factor signaling inhibitors. However, these approaches have shown limited efficacy; in fact, fulvestrant only elicits a response in approximately 7% of ERa-positive tumors that regrow under AI therapy, although its clinical use is justified based on a clinical benefit rate of 32% (Chia et al., 2008) . On the other hand, trials with combinations of AIs and growth factor signal inhibitors have not improved outcomes in most cases , except for recent results on novel combinations that are still under research (Baselga et al., 2009; Johnston et al., 2009) . In this scenario, the dynamic profiles of our model coincide with previous findings concerning the relevance of growth factor signaling but, importantly, our data also support a different explanation of the role of ERa: firstly, the switch from pS118-to pS167-ERa, an isoform known to be related to MAPK/AKT signaling (Campbell et al., 2001) , may indicate that sustained ERa expression is more a consequence of the activation of other pro-growth signals than a reflection of the importance of canonical ERa function; secondly, the fact that both over-and underexpressed gene sets during MCF7-LTED adaptation showed infra representation of ERa-responsive elements and were not enriched in 17bE2-mediated regulation from original MCF7 data (Carroll et al., 2006) , suggests a molecular landscape in which ERa, despite sustained expression, is no longer a highly active transcription modulator. This is in further agreement with the distinct increasing relevance of other transcription factors involved in cell proliferation, such as E2Fs, which has a key role in poor prognosis and nonresponse treatment signatures in breast cancer (Chang and Nevins, 2006; Vuaroqueaux et al., 2007; Yu et al., 2007; Zhang et al., 2007; Shen et al., 2008; Sole´et al., 2009) . In addition, when compared with tumor transcriptome profiles, the MCF7-LTED model bears resemblance to ERa-negative profiles.
The biological reprogramming toward a phenotype similar to ERa-negative conditions is akin to the relatively lower sensitivity of late-stage MCF7-LTED cells to fulvestrant but their increased sensitivity to FGFR-mediated signaling inhibition. Although these observations further underline the importance of considering dynamic profiles beyond short-term adaptation to first-line endocrine therapies, they also highlight a common scenario with related clinical settings. Recently, FGFR1 amplification and overexpression has been revealed as key in resistance to adjuvant tamoxifen (Turner et al., 2010b) , and integrative profiling has shown FGFR2 overexpression to be a promising therapeutic target in triple-negative breast cancer (Turner et al., 2010a) . Accordingly, the expression of FGFR1 and FGFR2 is partially regulated by E2F1 (Tashiro et al., 2003; Kanai et al., 2009) . Furthermore, targeting FGFR-mediated signaling that acts in an autocrine manner in a subset of breast cancers of poor prognosis has been shown to impair tumor outgrowth and metastasis (Dey et al., 2010) . These data, together with observations linking FGFR2 and risk of breast cancer (Easton et al., 2007; Hunter et al., 2007; Meyer et al., 2008) , further support that FGFR-mediated signaling is central in breast carcinogenesis.
Data obtained at different levels suggest a role of ERa expression increase linked to its non-genomic function. Indeed, genomic analysis supports the potential importance of ESR1 genomic amplification in acquisition of resistance. ESR1 locus gain, and its relevance in prognosis or prediction of response to endocrine therapies, is an area of open scientific debate. Two studies described a 11-20% frequency of amplification and improved prognosis for tumors showing this alteration, substantiating the importance of this biologic event on resistance to tamoxifen (Holst et al., 2007; Tomita et al., 2009) . Nevertheless, other reports appear to contradict these findings (Adelaide et al., 2008; Brown et al., 2008; Horlings et al., 2008; Reis-Filho et al., 2008; Vincent-Salomon et al., 2008) . Our work indicates that ESR1 gain may be a dynamic process; as such, ERa expression may respond to different events during resistance acquisition, with amplification being a possible landmark of estrogen independence. Owing to the potential clinical impact of this finding, further exploration using clinical samples is warranted.
Combined examination of those genes significantly deregulated during MCF7-LTED adaptation and those for which expression change is reported shortly after initiation of endocrine therapy is important, given the relevance of these early changes in the prediction of subsequent responses (Miller et al., 2007; Schild-Hay et al., 2009) . Our data recapitulate the early transcriptional changes but, given the dynamic behavior of these alterations, also suggest that caution should be taken when assessing their relevance to the overall benefit of the treatment in the clinical setting. This study expands on previous molecular and clinical observations proposing a mechanism of acquired resistance coordinated across biological levels and mostly independent of canonical ERa transcriptional function.
Materials and methods

Genomic and transcriptomic analyses
Genomic DNAs extracted with Qiagen DNeasy were hybridized onto CNV370-Quad 3 arrays (Illumina). Raw copy number values were obtained using the BeadStudio software with standard parameters. Copy number segmentation was computed using the Genome Alteration Detection Analysis algorithm (Pique-Regi et al., 2008) . Regions with consistent alteration over time points were computed using the G coefficient with categorized changes À1, 0 or 1. Expression microarray data have been deposited at Gene Expression Omnibus GSE20361. The RMA method implemented in BioConductor (Gentleman et al., 2004) was applied for background adjusting, normalization and summarization of microarray probes (Gautier et al., 2004) . For each probe-as appropriate, given potential transcriptional complexity and technical caveats (Alvarez et al., 2009 )-a linear model was fitted with expression as the response variable and time as the independent variable. To evaluate correlation between copy number and expression changes, probes were mapped to their genomic position in the May 2006 (hg18) version of the human genome and P-values computed using a w 2 goodness-of-fit test. For TF correlations, an expression dataset was used (van de Vijver et al., 2002) without filtering by ERa status and individually considering probes matching each Entrez gene identity. Differences in PCC distributions were assessed using the Mann-Whitney non-parametric test.
